Dr. Jones In the Media

ABC NewsDouble Chin Eliminator Injection: What to Know

Sydney, Lupkin. (WORLD NEWS) March 14, 2015

A new drug promises to get rid of double chins without surgery. Read More...

Perfect ScienceATX-101 yet to receive FDA's Final Approval

Diane, Bretting. (Perfect Science) March 16, 2015

A new drug, known as ATX-101, has been specifically designed to eliminate double chins without surgery. Read More...

PR WebASDS Elects New Officers, Board Members

San Diego, Calif. (PRWEB) November 07, 2014

Dr. Derek Jones M.D. elected to the Board of Directors of the American Society of Dermatologic Surgery. Read More...

Hollywood ReporterHollywood's Top Doctors: Best Dermatologists in Los Angeles

(THR Staff) September 10, 2014

Hollywood is a town obsessed with its health. So it's no surprise that everyone has an opinion on who are the best doctors in Los Angeles. Dr. Derek Jones is featured in the Hollywood Reporter.

CBSExcess Baggage? New Product Promises To Be Spanx For The Eyes

Sigell, (CBS Los Angeles) May 4, 2014

"Neotensil is a topical product, it's put underneath the eye," Dr. Derek Jones says, "and it basically compresses the eye bags and smooths the skin out." Read More...


Duddling, (Harpers Bazaar) April 15, 2014

Dr. Derek Jones talks about Fat-Dissolving Injections. Now awaiting FDA approval, ATX-101 is a synthetic version of a naturally occurring molecule in the body that breaks down dietary fat. Read More...



"In the JUVÉDERM VOLUMA XC clinical trial, physicians and patients were able to see instant and visible results, including correction of age-related volume loss in the cheek area and a more youthful appearance to the face." said Dr. Derek H. Jones, clinical investigator in the JUVÉDERM VOLUMA XC pivotal study. Read More...

Wall StreetWhat Dermatologists Don't Want You To Know


"Solution. Sick to the three-minute rule", says Dr. Jones, Los Angeles dermatologist and director of Skin and Laser Physicians of Beverley Hills. Read More...

Wall StreetFDA approves Juvéderm for adult midface volume loss

Onorati, (Dermatology Times) Oct 24, 2013

Results demonstrated that almost 50 percent of patients were maintaining optimal correction at two years, Dr. Derek Jones says, Clinical Investigator in the trial; however, many will maintain the correction longer. Read More...

Wall StreetVoluma, a Unique New Filler, Gets FDA Approval

Kron, (Allure) October 25, 2013

According to Dr. Derek Jones, a Beverly Hills dermatologist and the lead investigator in the study, "Voluma lasted in cheeks for up to two years," at least twice the endurance of Restylane®. Read More...

Wall Street8 Skin Mistakes You Don't Know You're Making


"The mistake of over-exfoliating with scrubs and peels can cause excessive dryness and greater visibility of fine lines and wrinkles", says Dr. Derek Jones, founder and director of Skin Care and Laser Physicians of Beverley Hill and clinical associate professor at UCLA. The quick fix, Read More...

Wall Street2 Futuristic Skin Treatments That Could Change Everything

MCINTYRE, (Refinery 29) Oct 28, 2013

"This is a paradigm shift in the way we think about rejuvenating the face", says Dr. Derek Jones (one of the researchers on the just-released clinical study and a consultant for Allergan, the makers of Voluma). Read More...

Dr. Derek H. Jones of Skin Care and Laser Physicians of Beverly Hills is featured in the Spring/Summer 2012 edition of NewBeauty® magazine. The world’s most unique beauty magazine, NewBeauty is the ultimate aesthetic resource for “everything beauty,” covering subjects from advancements in facial fillers to the most luxurious spa treatments to the newest wrinkle-reducing serums and everything in between.


Dr. Derek Jones demonstrates Belotero on "The Doctors":

Dr. Jones was the Lead Investigator on the FDA trial that brought the New JUVEDERM VOLUMA XC into the United States.


Dr. Derek Jones demonstrates Anti Wrinkle Treatment XEOMIN®

Dr. Derek Jones talks about a new non-invasive treatment that supports and compresses the under-eye area, Neotensil™.